SCHEMBL13360768

SCHEMBL13360768

CCC(=O)N1CCC(C)(C)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
OPRM1 P35372 1/20 0.46
BLM P54132 1/20 0.43
CHRNB2 P17787 3/20 0.41
CHRNA3 P32297 3/20 0.41
CHRNA4 P43681 3/20 0.41
CHRNB3 Q05901 1/20 0.41
CHRNA6 Q15825 1/20 0.41
EPHX2 P34913 3/20 0.41
CHRNB4 P30926 2/20 0.39
CHRNA7 P36544 2/20 0.39
NAMPT P43490 1/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
EPHX1 P07099 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
OPRD1 P41143 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16621834 0.89 ALDH1A1 (0.55) ALDH1A1OPRM1BLMCHRNB2CHRNA3
SCHEMBL14277668 0.84 ALDH1A1 (0.50) ALDH1A1OPRM1BLMCHRNB2CHRNA3
SCHEMBL13804168 0.83 ALDH1A1 (0.48) ALDH1A1OPRM1BLMCHRNB2CHRNA3
SCHEMBL16887630 0.83 ALDH1A1 (0.48) ALDH1A1OPRM1BLMCHRNB2CHRNA3
SCHEMBL327615 0.82 ALDH1A1 (0.47) ALDH1A1OPRM1BLMCHRNB2CHRNA3
SCHEMBL15998851 0.82 ALDH1A1 (0.47) ALDH1A1OPRM1BLMCHRNB2CHRNA3
SCHEMBL14417828 0.82 NAMPT (0.42) ALDH1A1EPHX2NAMPTMEN1TSHR
SCHEMBL8903167 0.80 NAMPT (0.37) ALDH1A1OPRM1EPHX2NAMPTMEN1
SCHEMBL10074073 0.80 ALDH1A1 (0.45) ALDH1A1OPRM1BLMCHRNB2CHRNA3
SCHEMBL4438715 0.80 ALDH1A1 (0.53) ALDH1A1NAMPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382906-A1 NOVEL JAK INHIBITOR COMPOUNDS, METHODS FOR SYNTHESIZING SAME AND USE THEREOF Galderma Holding SA (CH) 2023-11-30 US disclosed
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands ASTRAZENECA AB (SE) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382906-A1 NOVEL JAK INHIBITOR COMPOUNDS, METHODS FOR SYNTHESIZING SAME AND USE THEREOF JAK1, JAK2, JAK3 ALDH1A1 2193/4885OPRM1 4395/4885BLM 3595/4885
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands CNR1, CNR2, OPRL1 ALDH1A1 1706/4885OPRM1 4/4885BLM 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.